Pacer Advisors Inc. Grows Stake in Iqvia Holdings Inc (NYSE:IQV)

Pacer Advisors Inc. lifted its position in Iqvia Holdings Inc (NYSE:IQV) by 19,707.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,817 shares of the medical research company’s stock after buying an additional 18,722 shares during the period. Pacer Advisors Inc.’s holdings in Iqvia were worth $2,670,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in IQV. State Street Corp lifted its position in Iqvia by 1.9% during the first quarter. State Street Corp now owns 7,942,211 shares of the medical research company’s stock valued at $856,647,000 after purchasing an additional 149,014 shares in the last quarter. Longview Partners Guernsey LTD purchased a new position in Iqvia during the first quarter valued at $742,551,000. Alliancebernstein L.P. lifted its position in Iqvia by 24.7% during the first quarter. Alliancebernstein L.P. now owns 4,897,269 shares of the medical research company’s stock valued at $528,219,000 after purchasing an additional 969,033 shares in the last quarter. Geode Capital Management LLC lifted its position in Iqvia by 0.6% during the first quarter. Geode Capital Management LLC now owns 2,781,344 shares of the medical research company’s stock valued at $299,420,000 after purchasing an additional 17,399 shares in the last quarter. Finally, Morgan Stanley lifted its position in Iqvia by 2.4% during the first quarter. Morgan Stanley now owns 2,390,996 shares of the medical research company’s stock valued at $257,893,000 after purchasing an additional 56,025 shares in the last quarter. Hedge funds and other institutional investors own 88.49% of the company’s stock.

Several research firms recently weighed in on IQV. Stifel Nicolaus lifted their target price on Iqvia from $159.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wells Fargo & Co lifted their target price on Iqvia from $155.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Piper Sandler lifted their target price on Iqvia from $115.00 to $138.00 in a research report on Wednesday, April 29th. Citigroup boosted their price objective on Iqvia from $160.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Finally, Robert W. Baird boosted their price objective on Iqvia from $156.00 to $180.00 and gave the company an “outperform” rating in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $165.11.

In other Iqvia news, insider Ari Bousbib sold 19,443 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $150.00, for a total transaction of $2,916,450.00. Following the sale, the insider now directly owns 671,478 shares of the company’s stock, valued at $100,721,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Group Holdings (Sbs) Advis Tpg sold 2,919,051 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $159.12, for a total value of $464,479,395.12. The disclosure for this sale can be found here. Insiders have sold 2,984,574 shares of company stock worth $474,768,645 over the last three months. 6.00% of the stock is currently owned by insiders.

Shares of IQV stock opened at $158.39 on Friday. Iqvia Holdings Inc has a 12-month low of $81.79 and a 12-month high of $169.14. The company has a current ratio of 1.10, a quick ratio of 1.09 and a debt-to-equity ratio of 2.11. The stock’s 50-day moving average price is $145.51 and its 200-day moving average price is $140.52. The stock has a market capitalization of $30.30 billion, a price-to-earnings ratio of 232.93, a price-to-earnings-growth ratio of 2.80 and a beta of 1.32.

Iqvia (NYSE:IQV) last issued its earnings results on Wednesday, July 22nd. The medical research company reported $1.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Iqvia had a return on equity of 17.90% and a net margin of 1.21%. The firm had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the previous year, the firm posted $1.53 earnings per share. As a group, research analysts predict that Iqvia Holdings Inc will post 5.72 EPS for the current fiscal year.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: What is a CD ladder?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.